Literature DB >> 28372929

Cystic fibrosis in the era of precision medicine.

Shruti M Paranjape1, Peter J Mogayzel2.   

Abstract

The treatment of people with cystic fibrosis (CF) has been transformed by the availability of drugs that target the basic chloride defect in the disease. The use of drugs that target specific molecular defects embodies the goals of precision medicine, which incorporate preventive and therapeutic strategies and takes into account differences among individuals. However, the entirety of CF care, from diagnosis to understanding the clinical phenotype and developing a therapeutic strategy, depends on taking into account individual characteristics to achieve optimal outcomes. Future therapies are likely to be even more individualized ushering in a new era of precision medicine.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  CFTR; Cystic Fibrosis; Genotype; Phenotype; Precision Medicine

Mesh:

Year:  2017        PMID: 28372929     DOI: 10.1016/j.prrv.2017.03.001

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  9 in total

1.  Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations.

Authors:  Lisa B Feng; Scott D Grosse; Ridgely Fisk Green; Aliza K Fink; Gregory S Sawicki
Journal:  Health Aff (Millwood)       Date:  2018-05       Impact factor: 6.301

2.  Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Recurrent Acute Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Mark E Lowe; Marc T Goodman; Gregory A Coté; Marshall J Glesby; Mark Haupt; Nicholas J Schork; Vikesh K Singh; Dana K Andersen; Stephen J Pandol; Aliye Uc; David C Whitcomb
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

Review 3.  [Rare metabolic disorders and urolithiasis].

Authors:  C Fisang; N Laube
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

4.  Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.

Authors:  Apparao B Kummarapurugu; Daniel K Afosah; Nehru Viji Sankaranarayanan; Rahaman Navaz Gangji; Shuo Zheng; Thomas Kennedy; Bruce K Rubin; Judith A Voynow; Umesh R Desai
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

Review 5.  Asthma: Differential Diagnosis and Comorbidities.

Authors:  Nicola Ullmann; Virginia Mirra; Antonio Di Marco; Martino Pavone; Federica Porcaro; Valentina Negro; Alessandro Onofri; Renato Cutrera
Journal:  Front Pediatr       Date:  2018-10-03       Impact factor: 3.418

6.  A Peptide Nucleic Acid against MicroRNA miR-145-5p Enhances the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Calu-3 Cells.

Authors:  Enrica Fabbri; Anna Tamanini; Tiziana Jakova; Jessica Gasparello; Alex Manicardi; Roberto Corradini; Giuseppe Sabbioni; Alessia Finotti; Monica Borgatti; Ilaria Lampronti; Silvia Munari; Maria Cristina Dechecchi; Giulio Cabrini; Roberto Gambari
Journal:  Molecules       Date:  2017-12-29       Impact factor: 4.411

Review 7.  Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis.

Authors:  Cecilia Velino; Francesca Carella; Alessio Adamiano; Maurizio Sanguinetti; Alberto Vitali; Daniele Catalucci; Francesca Bugli; Michele Iafisco
Journal:  Front Bioeng Biotechnol       Date:  2019-12-17

8.  Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management.

Authors:  Tyler R Ray; Maja Ivanovic; Paul M Curtis; Daniel Franklin; Kerem Guventurk; William J Jeang; Joseph Chafetz; Hannah Gaertner; Grace Young; Steve Rebollo; Jeffrey B Model; Stephen P Lee; John Ciraldo; Jonathan T Reeder; Aurélie Hourlier-Fargette; Amay J Bandodkar; Jungil Choi; Alexander J Aranyosi; Roozbeh Ghaffari; Susanna A McColley; Shannon Haymond; John A Rogers
Journal:  Sci Transl Med       Date:  2021-03-31       Impact factor: 17.956

Review 9.  Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?

Authors:  Roos van Westrhenen; Katherine J Aitchison; Magnus Ingelman-Sundberg; Marin M Jukić
Journal:  Front Psychiatry       Date:  2020-03-12       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.